Deucravacitinib: A Safe and Effective Choice for Treating Psoriasis

Recent findings from the Poetyk Pso study, presented at the European Academy of Dermatology and Venereology (EADV) Congress in Berlin by Bristol Myers Squibb, highlight the sustained effectiveness and consistent safety of deucravacitinib in treating moderate to severe plaque psoriasis over three years. At the 148-week mark, the study demonstrated robust clinical response rates, including 73.2% for PASI 75, 48.1% for PASI 90, and 54.1% for sPGA 0/1 with continuous deucravacitinib treatment. Dr. April Armstrong, lead investigator of the POETYK PSO program, expressed confidence in deucravacitinib as the preferred oral treatment for adults with this condition, emphasizing its long-term efficacy and well-established safety profile.

The safety and efficacy analysis involved 1,519 patients treated with deucravacitinib across various studies, showing sustained clinical efficacy and a consistent safety profile. The global Phase 3 studies, POETYK PSO-1 and POETYK PSO-2, confirmed the effectiveness and safety of deucravacitinib in treating moderate to severe plaque psoriasis, impacting over 100 million people worldwide. Despite the availability of systemic therapies, many patients with moderate to severe psoriasis lack adequate treatment, leading to dissatisfaction and emotional well-being impacts. Psoriasis is associated with various comorbidities, emphasizing the need for improved therapeutic options.

Are you an English-speaking professional residing in Rome? List your services on to connect with clients in need of immediate assistance. You won’t have to wait for payment; clients will pay you right after your services are completed.

Reproduction or distribution of any material on this blog without authorization is strictly forbidden. ‘Sista’ is a registered trademark.

Share This Post

More To Explore